公开(公告)号：US20210228731A1

公开(公告)日：2021-07-29

申请号：US17253584

申请日：2019-06-19

Applicant: NOVARTIS AG

Inventor： Anthony Edward BOITANO ,  Matthew T. BURGER ,  Susan E. CELLITTI ,  Michael Paul COOKE ,  Catrin FINNER ,  Bernhard Hubert GEIERSTANGER ,  Si-Tuen LEE-HOEFLICH ,  HongNgoc Thi PHAM ,  Siew Ho SCHLEYER ,  Kathrin TISSOT ,  Tetsuo UNO ,  Yongqin WAN ,  Ben WEN ,  Qiang ZHANG

IPC: A61K47/68 ,  C07K16/28 ,  A61K38/07

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

公开(公告)号：US20230091510A1

公开(公告)日：2023-03-23

申请号：US17612280

申请日：2020-05-19

Applicant: Novartis AG

Inventor： Zhuoliang CHEN ,  Katsumasa NAKAJIMA ,  Matthew T. BURGER ,  Joseph Anthony D'ALESSIO ,  Eric MCNEILL ,  Mark G, PALMERO ,  Bing YU ,  Qiang ZHANG

IPC: A61K47/68 ,  A61K47/54 ,  A61K47/60 ,  A61K47/61 ,  A61P35/00 ,  C07K16/28 ,  C07K5/062

Abstract: Provided herein are linkers, linker-drug groups and anti-body-drug conjugates comprising hydrophilic groups.